CooperCompanies Elects Maria Rivas, MD to Board of Directors
May 12 2021 - 4:15PM
CooperCompanies (NYSE: COO) announced today that its Board of
Directors has elected Dr. Maria Rivas as an independent director,
effective July 1, 2021.
“We are pleased to welcome Maria to our Board of Directors,”
said Al White, President and CEO. “Maria brings a very valuable
perspective with her background in fertility, medical affairs,
product development, and global regulatory. We look forward to her
advice and contributions as CooperCompanies continues to grow.”
Dr. Rivas currently serves as Chief Medical Officer and Senior
Vice President for the healthcare business of Merck KGaA,
Darmstadt, Germany (which operates as EMD Serono in the US and
Canada) where she leads the Global Pharmacovigilance, Medical
Affairs and Evidence and Value Development (HEOR) teams in over 90
countries.
Prior to that, Dr. Rivas served as Senior Vice President of
Global Medical Affairs at Merck & Co (MSD), as Vice President
of Global Medical Affairs at Abbvie, as Vice President of Oncology,
General Medicine and Diagnostic Imaging Medical Affairs at Bayer
Healthcare, and in various roles at Eli Lilly including Head of US
Women’s Health Medical Affairs. Before joining Eli Lilly, Dr. Rivas
was in private practice as an endocrinologist in Puerto Rico.
Born in Cuba, Dr. Rivas grew up in Puerto Rico and still has
many family, friends and professional connections there. In 2020,
she was named among the Top 100 Most Influential Latinas by Latino
Leaders Magazine.
Cooper’s Board of Directors has welcomed several new directors
and leaders in recent months. In November 2020, Teresa S. Madden
was elected to the Board as an independent director. In March,
Robert S. Weiss was elected Chairman of the Board, and William A.
Kozy was elected Vice Chairman and Lead Director replacing A.
Thomas Bender and Allan E. Rubenstein, M.D., respectively, who
retired after many years of service.
With the addition of Dr. Rivas, the Board will be comprised of
eight directors, six of whom are independent. Cooper’s Board
members are:
- Robert S. Weiss, Chairman of the Board
- William (Bill) A. Kozy, Vice Chairman and Lead Director
- Colleen E. Jay, Director
- Jody S. Lindell, Director
- Teresa S. Madden, Director
- Gary S. Petersmeyer, Director
- Dr. Maria Rivas, Director (effective July 1, 2021)
- Albert G. White III, President & Chief Executive Officer,
CooperCompanies
About CooperCompaniesCooperCompanies ("Cooper")
is a global medical device company publicly traded on the NYSE
(NYSE: COO). Cooper operates through two business units,
CooperVision and CooperSurgical. CooperVision brings a refreshing
perspective on vision care with a commitment to developing a wide
range of high-quality products for contact lens wearers and
providing focused practitioner support. CooperSurgical is committed
to advancing the health of women, babies and families with its
diversified portfolio of products and services focusing on medical
devices and fertility & genomics. Headquartered in San Ramon,
CA, Cooper has a workforce of more than 12,000 with products sold
in over 100 countries. For more information, please visit
www.coopercos.com.
Contact:Kim DuncanVice President, Investor Relations and Risk
Management925-460-3663ir@cooperco.com
Cooper Companies (NYSE:COO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cooper Companies (NYSE:COO)
Historical Stock Chart
From Apr 2023 to Apr 2024